OMB Individually Reported

AI-assisted Platform for Clinical Pharmacology Review

Low riskExact public inventory row

Description

The AI solution addresses inefficiency in the clinical pharmacology review process by reducing time reviewers spend on routine tasks, allowing them to focus their expertise on complex scientific analysis and decision-making that truly requires their specialized knowledge.

Detailed example

AI assisted answers to list of tasks in selected task groups for clinical pharmacology review, including supporting information helping reviewers to identify the source of information from original documents.

AI / analytics pattern

Generative AI: AI that generates new or synthetic content (e.g., images, videos, audio, text, code).

Automation level / stage

a) Pre-deployment – The use case is in a development or acquisition status.

Expected benefit

The AI integration is expected to enhance agency efficiency by optimizing reviewer time allocation, allowing them to focus on high-value tasks requiring specialized expertise. This leads to improved productivity, reduced delays, and enhanced overall performance. For the public, this translates to more timely and higher quality regulatory reviews of new medications.

Controls / human review

ATO: Not reported; PIA: Not published